vs
Pinnacle West Capital（PNW）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Pinnacle West Capital的季度营收约是Revvity的1.5倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs 1.6%，领先11.2%），Revvity同比增速更快（5.9% vs 3.0%），Revvity自由现金流更多（$161.8M vs $-192.7M），过去两年Revvity的营收复合增速更高（9.0% vs 8.9%）
Pinnacle West Capital是美国公用事业控股企业，旗下拥有亚利桑那州规模最大的公用事业公司亚利桑那公共服务（APS）。公司于纽约证券交易所上市，是标普500指数成分股，运营受亚利桑那州公司委员会监管。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PNW vs RVTY — 直观对比
营收规模更大
PNW
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出2.9%
3.0%
净利率更高
RVTY
高出11.2%
1.6%
自由现金流更多
RVTY
多$354.5M
$-192.7M
两年增速更快
RVTY
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $17.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 10.7% | 14.5% |
| 净利率 | 1.6% | 12.7% |
| 营收同比 | 3.0% | 5.9% |
| 净利润同比 | 798.0% | 3.9% |
| 每股收益（稀释后） | $0.12 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PNWRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.8B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.8B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $951.7M | $649.9M |
净利润PNWRVTY
| Q4 25 | $17.6M | $98.4M | ||
| Q3 25 | $417.5M | $46.7M | ||
| Q2 25 | $196.9M | $53.9M | ||
| Q1 25 | $-338.0K | $42.2M | ||
| Q4 24 | $-2.5M | $94.6M | ||
| Q3 24 | $399.3M | $94.4M | ||
| Q2 24 | $208.1M | $55.4M | ||
| Q1 24 | $21.2M | $26.0M |
毛利率PNWRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率PNWRVTY
| Q4 25 | 10.7% | 14.5% | ||
| Q3 25 | 32.0% | 11.7% | ||
| Q2 25 | 22.6% | 12.6% | ||
| Q1 25 | 5.5% | 10.9% | ||
| Q4 24 | 7.7% | 16.3% | ||
| Q3 24 | 30.9% | 14.3% | ||
| Q2 24 | 24.0% | 12.4% | ||
| Q1 24 | 7.0% | 6.8% |
净利率PNWRVTY
| Q4 25 | 1.6% | 12.7% | ||
| Q3 25 | 22.9% | 6.7% | ||
| Q2 25 | 14.5% | 7.5% | ||
| Q1 25 | -0.0% | 6.4% | ||
| Q4 24 | -0.2% | 13.0% | ||
| Q3 24 | 22.6% | 13.8% | ||
| Q2 24 | 15.9% | 8.0% | ||
| Q1 24 | 2.2% | 4.0% |
每股收益（稀释后）PNWRVTY
| Q4 25 | $0.12 | $0.86 | ||
| Q3 25 | $3.39 | $0.40 | ||
| Q2 25 | $1.58 | $0.46 | ||
| Q1 25 | $-0.04 | $0.35 | ||
| Q4 24 | $-0.04 | $0.77 | ||
| Q3 24 | $3.37 | $0.77 | ||
| Q2 24 | $1.76 | $0.45 | ||
| Q1 24 | $0.15 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.0B | $7.3B |
| 总资产 | $30.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PNWRVTY
| Q4 25 | $6.6M | $919.9M | ||
| Q3 25 | $30.9M | $931.4M | ||
| Q2 25 | $18.8M | $991.8M | ||
| Q1 25 | $10.0M | $1.1B | ||
| Q4 24 | $3.8M | $1.2B | ||
| Q3 24 | $49.2M | $1.2B | ||
| Q2 24 | $4.0M | $2.0B | ||
| Q1 24 | $9.6M | $1.7B |
股东权益PNWRVTY
| Q4 25 | $7.0B | $7.3B | ||
| Q3 25 | $7.2B | $7.4B | ||
| Q2 25 | $6.7B | $7.6B | ||
| Q1 25 | $6.7B | $7.6B | ||
| Q4 24 | $6.8B | $7.7B | ||
| Q3 24 | $6.6B | $7.9B | ||
| Q2 24 | $6.2B | $7.9B | ||
| Q1 24 | $6.2B | $7.8B |
总资产PNWRVTY
| Q4 25 | $30.0B | $12.2B | ||
| Q3 25 | $29.9B | $12.1B | ||
| Q2 25 | $29.2B | $12.4B | ||
| Q1 25 | $27.2B | $12.4B | ||
| Q4 24 | $26.1B | $12.4B | ||
| Q3 24 | $26.3B | $12.8B | ||
| Q2 24 | $25.7B | $13.4B | ||
| Q1 24 | $24.8B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $476.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-192.7M | $161.8M |
| 自由现金流率自由现金流/营收 | -17.1% | 21.0% |
| 资本支出强度资本支出/营收 | 59.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 27.09× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-819.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PNWRVTY
| Q4 25 | $476.8M | $182.0M | ||
| Q3 25 | $665.0M | $138.5M | ||
| Q2 25 | $261.4M | $134.3M | ||
| Q1 25 | $401.9M | $128.2M | ||
| Q4 24 | $439.5M | $174.2M | ||
| Q3 24 | $633.2M | $147.9M | ||
| Q2 24 | $189.8M | $158.6M | ||
| Q1 24 | $347.4M | $147.6M |
自由现金流PNWRVTY
| Q4 25 | $-192.7M | $161.8M | ||
| Q3 25 | $42.0M | $120.0M | ||
| Q2 25 | $-448.1M | $115.5M | ||
| Q1 25 | $-220.7M | $112.2M | ||
| Q4 24 | $-92.1M | $149.8M | ||
| Q3 24 | $-32.7M | $125.6M | ||
| Q2 24 | $-344.2M | $136.6M | ||
| Q1 24 | $-170.4M | $129.7M |
自由现金流率PNWRVTY
| Q4 25 | -17.1% | 21.0% | ||
| Q3 25 | 2.3% | 17.2% | ||
| Q2 25 | -33.0% | 16.0% | ||
| Q1 25 | -21.4% | 16.9% | ||
| Q4 24 | -8.4% | 20.5% | ||
| Q3 24 | -1.8% | 18.4% | ||
| Q2 24 | -26.3% | 19.7% | ||
| Q1 24 | -17.9% | 20.0% |
资本支出强度PNWRVTY
| Q4 25 | 59.3% | 2.6% | ||
| Q3 25 | 34.2% | 2.6% | ||
| Q2 25 | 52.2% | 2.6% | ||
| Q1 25 | 60.3% | 2.4% | ||
| Q4 24 | 48.5% | 3.4% | ||
| Q3 24 | 37.6% | 3.3% | ||
| Q2 24 | 40.8% | 3.2% | ||
| Q1 24 | 54.4% | 2.7% |
现金转化率PNWRVTY
| Q4 25 | 27.09× | 1.85× | ||
| Q3 25 | 1.59× | 2.97× | ||
| Q2 25 | 1.33× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.59× | 1.57× | ||
| Q2 24 | 0.91× | 2.87× | ||
| Q1 24 | 16.41× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PNW
| Electricand Transmission Service | $1.1B | 100% |
| Other Services | $4.4M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
